Study on <i>Helicobacter pylori</i> serotypes, upper gastrointestinal diseases and effect of <i>Helicobacter pylori</i> eradication

GUO Jinzhi; TANG Shengjun; WANG Delu; QIAN Likang; ZHANG Yuanrui

doi:10.7619/jcmp.20220380

Journal of Clinical Medicine in Practice > 2022 > 26(7): 128-131. > DOI: 10.7619/jcmp.20220380

GUO Jinzhi, TANG Shengjun, WANG Delu, QIAN Likang, ZHANG Yuanrui. Study on Helicobacter pylori serotypes, upper gastrointestinal diseases and effect of Helicobacter pylori eradication[J]. Journal of Clinical Medicine in Practice, 2022, 26(7): 128-131. DOI: 10.7619/jcmp.20220380

Citation:

PDF (532 KB)

Study on Helicobacter pylori serotypes, upper gastrointestinal diseases and effect of Helicobacter pylori eradication

1.
Department of Gastroenterology,Tongling Fourth People′s Hospital in Anhui Province, Tongling, Anhui, 244000
2.
Laboratory Department, Tongling Fourth People's Hospital in Anhui Province, Tongling, Anhui, 244000

More Information

Received Date: February 07, 2022
Available Online: April 14, 2022
Published Date: April 14, 2022

Graphical Abstract

Abstract

Abstract

Objective   To observe Helicobacter pylori (Hp) serotypes, and compare eradication effects of different serological typing.
Methods   A total of 267 patients with upper gastrointestinal symptoms were collected as study objects and were divided into chronic gastritis group(n=90), gastric polyps group(n=76) and peptic ulcer group(n=101). Venous blood was drawn from all patients, and expressions of Hp antibodies, including urease A(UreA), urease B (UreB), cytotoxin associated protein A (CagA) and vacuolating toxin associated protein A (VacA)in serum were detected. Hp infection rate and positive rates of UreA, UreB, CagA and VacA were compared in each group. Hp positive patients were treated with quadruple regimen, and Hp eradication rates of patients with different Hp types were compared.
Results   The total Hp infection rate of 267 patients was 67.04%. The Hp infection rates of chronic gastritis group, gastric polyp group and peptic ulcer group were 61.11%, 51.32% and 84.16%, respectively. The Hp infection rate of the peptic ulcer group was higher than that of the chronic gastritis group and the gastric polyp group (P < 0.05). There was no significant difference in Hp infection rate between the chronic gastritis group and the gastric polyp group (P>0.05). The positive rates of UreA and VacA in the peptic ulcer group were higher than those in the chronic gastritis group and the gastric polyp group (P < 0.05). There was no significant difference in the positive rate of UreA and VacA between chronic gastritis group and gastric polyp group (P>0.05). The positive rate of UreB in the peptic ulcer group(93.07%) was higher than that in the chronic gastritis group (78.89%) and gastric polyp group(61.84%), and was higher in the chronic gastritis group than that in the gastric polyp group (P < 0.05). The positive rate of CagA in the peptic ulcer group(66.34%) was higher than 46.05% in the gastric polyp group (P < 0.05). There was no significant difference in CagA positive rate between the chronic gastritis group and gastric polyp group, between the chronic gastritis group and the peptic ulcer group (P>0.05). In the chronic gastritis group, gastric polyp group and peptic ulcer group, the infection rates of Hp type I were 83.64%, 87.18% and 77.65%, respectively, which were higher than that of Hp type Ⅱ. After quadruple regimen, the eradication rate of Hp type I was higher than that of type Ⅱ(86.99%versus 69.70%, P < 0.05).
Conclusion   The infection rates of Hp typeⅠ in patients with chronic gastritis, gastric polyp and peptic ulcer are higher than those with Hp typeⅡ, the infection rate of Hp and positive rate of Hp antibody in patients with peptic ulcer are higher than those of chronic gastritis and gastric polyp, and the eradication rate of Hp type Ⅰ is higher than that of Hp type Ⅱ.
- Helicobacter pylori,
- serological typing,
- peptic ulcer,
- gastric polyps,
- chronic gastritis,
- eradication therapy

FullText(HTML)

References (17)

References

[1]	ABDELMONEM M, ELSHAMSY M, WASIM H, et al. Epidemiology of Helicobacter pyloriin delta Egypt[J]. Am J ClinPathol, 2020, 154(Suppl 1): S130.
[2]	王建保. 分析健康体检人群中幽门螺杆菌感染率的检出情况[J]. 中国社区医师, 2021, 31(7): 137-138. doi: 10.3969/j.issn.1007-614x.2021.07.067
[3]	王楠, 刘雨, 陈改杰. 健康体检人群幽门螺杆菌感染现状分析[J]. 河南医学研究, 2018, 27(14): 2548-2549. doi: 10.3969/j.issn.1004-437X.2018.14.024
[4]	庞训雷, 李莉, 王艳红, 等. 不同Hp分型增生性胃息肉患者血清PGⅠ、PGⅡ、G17水平变化及意义[J]. 山东医药, 2018, 58(24): 67-69. doi: 10.3969/j.issn.1002-266X.2018.24.020
[5]	陈晓非, 程荣贵, 王绍峰. 长治地区消化道疾病与幽门螺杆菌分型分析[J]. 当代医学, 2020, 26(29): 90-92. doi: 10.3969/j.issn.1009-4393.2020.29.035
[6]	FILOMENA A, GUENTHER A, PLANATSCHER H, et al. Performance of a multiplex serological Helicobacter pylori assay on a novel microfluidic assay platform[J]. Proteomes, 2017, 5(4): 24. doi: 10.3390/proteomes5040024
[7]	颜晰, 樊建平, 王苋, 等. 含Hp特异性抗体羊奶2种检测方法的比较及初步临床效果[J]. 河北医科大学学报, 2020, 41(1): 94-98. doi: 10.3969/j.issn.1007-3205.2020.01.022
[8]	常丽丽, 高鹤, 封博华, 等. 胃底腺息肉和胃增生性息肉伴胆汁反流患者幽门螺杆菌感染状况[J]. 中华消化杂志, 2018, 38(8): 557-559. doi: 10.3760/cma.j.issn.0254-1432.2018.08.011
[9]	张秀莲, 黄玉莲, 陈飞旭. 不同幽门螺杆菌感染分型的胃息肉患者胃蛋白酶原和胃泌素水平的变化[J]. 当代医学, 2019, 25(19): 73-75. doi: 10.3969/j.issn.1009-4393.2019.19.029
[10]	LAINE L, BARKUN A N, SALTZMAN J R, et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding[J]. Am J Gastroenterol, 2021, 116(5): 899-917. doi: 10.14309/ajg.0000000000001245
[11]	汪海涛, 张杰, 蒋晓忠, 等. 含铋四联疗法联合双歧杆菌四联活菌片治疗幽门螺杆菌感染阳性消化性溃疡疗效观察[J]. 临床军医杂志, 2018, 46(3): 329-330, 333. https://www.cnki.com.cn/Article/CJFDTOTAL-JYGZ201803027.htm
[12]	何媛, 赵晶, 林泳. 血清幽门螺杆菌抗体分型与胃部疾病的关系研究[J]. 中国全科医学, 2019, 22(36): 4424-4428. doi: 10.12114/j.issn.1007-9572.2019.00.729
[13]	涂宏飞, 李莉, 费素娟. 不同Hp分型消化性溃疡患者血清IL-32、IL-33水平变化及意义[J]. 新医学, 2020, 51(3): 195-198. doi: 10.3969/j.issn.0253-9802.2020.03.008
[14]	LAVANYA J, JAYALAKSHMI J, VENKATAKRISHNAN L, et al. CagA and VacA genes of Helicobacter pylori and their clinical relevance[J]. Indian J PatholMicrobiol, 2018, 61(1): 66-69.
[15]	袁林, 丁松泽, 张延瑞, 等. 不同类型幽门螺杆菌在慢性胃病中感染情况及对胃泌素-17和胃蛋白酶原的影响[J]. 中华实用诊断与治疗杂志, 2020, 34(4): 382-385. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD202004015.htm
[16]	江堤, 廖素环, 邓惠钊, 等. 幽门螺杆菌抗体分型在诊治上消化道疾病中的意义[J]. 湘南学院学报: 医学版, 2018, 20(3): 29-32. https://www.cnki.com.cn/Article/CJFDTOTAL-CZYG201803008.htm
[17]	朱明飞, 赵丽娟, 王立军. 幽门螺杆菌分型检测及其与幽门螺杆菌根除率的关系研究[J]. 西北国防医学杂志, 2018, 39(9): 606-610. https://www.cnki.com.cn/Article/CJFDTOTAL-XBGY201809014.htm

Cited By

Cited by

Periodical cited type(12)

1.	徐佳，张保茹，杨婷. 血清同型半胱氨酸、HDL-C、Lp(a)水平在幽门螺杆菌感染患者中的价值. 吉林医学. 2025(03): 568-571 .
2.	朱晨，孙长贵，王正福. 益生菌联合四联疗法根除幽门螺杆菌的效果评价. 中外医疗. 2024(11): 79-82 .
3.	涂细国. 不同药物方案治疗幽门螺杆菌胃炎活动期疗效分析. 现代诊断与治疗. 2024(08): 1214-1216 .
4.	鲍英. 高频电切术与EMR治疗消化道息肉的效果分析. 中国实用医药. 2024(15): 53-56 .
5.	郭彩云，张娟娟，张永利. 慢性胃炎Hp感染状况、菌株分型与胃黏膜病变的相关性研究. 中国基层医药. 2024(10): 1479-1483 .
6.	高燕，张丹，李倩，张俊波，刘柳，朱亚男，郭姗姗. 体检人群幽门螺杆菌感染情况及其与高血压、糖脂代谢的相关性. 实用临床医药杂志. 2024(23): 100-104 . 本站查看
7.	李玫霖，沈栋林，刘立，房路路，王晓悦. 康复新液辅助治疗儿童幽门螺杆菌相关性胃炎血清学指标的变化及不同分型的临床价值研究. 中国中西医结合消化杂志. 2023(03): 214-219 .
8.	张益宇，方向明. 胃息肉与幽门螺杆菌感染关系的研究进展. 临床内科杂志. 2023(04): 284-286 .
9.	马宁璟，陈绍斌. 益生菌联合铋剂四联疗法对不同分型幽门螺杆菌根除率的影响. 中国微生态学杂志. 2023(07): 836-842 .
10.	陆瑛，杨晓军. 血清PG、G-17、IL-10在不同菌型Hp感染慢性非萎缩性胃炎中的表达及对预后评估的价值分析. 中国现代药物应用. 2023(18): 34-38 .
11.	郑媛媛，胡团敏. 闽南地区某部队幽门螺杆菌感染及基因型分布情况. 医学研究与战创伤救治. 2023(06): 604-608 .
12.	王芯，郑世勤，付青海，何旭东. 幽门螺杆菌及其分型与消化道疾病关系的研究进展. 国际消化病杂志. 2023(06): 367-370 .

Other cited types(8)

Get Citation

PDF

XML

Article views (229) PDF downloads (20) Cited by(20)

Turn off MathJax

Article Contents

Abstract

References

Study on Helicobacter pylori serotypes, upper gastrointestinal diseases and effect of Helicobacter pylori eradication

Abstract

References

Cited by

Periodical cited type(12)

Other cited types(8)

Catalog

Export File

Citation

Format

Content